Comparison of chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for steroid-refractory acute graft-versus-host disease
In conclusion, no significant differences were observed in efficacy or adverse events between chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for the treatment of SR-aGVHD. Further studies with larger cohorts are necessary to validate these findings.
Authors
- S. feng
- Xinhui Zheng (ORCID: https://orcid.org/0009-0005-6551-1201)
- Erlie Jiang (ORCID: https://orcid.org/0000-0003-0237-6063)
- J J Wei
- Yigeng Cao
- Ni Lu (ORCID: https://orcid.org/0009-0002-2721-9224)
- Weihua Zhai
- Yawei Zheng
- Aiming Pang
- Xin Chen
- Mingzhe Han
- Yunxia Zhou
- Rongli Zhang
- Donglin Yang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.3389/fimmu.2025.1660452
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City
- National Science and Technology Major Project
- Fundamental Research Funds for the Central Universities